U.S. regulators have recommended pausing the use of Johnson & Johnson's (JNJ.N) COVID-19 vaccine, as they investigate rare blood clotting in six women.
EXPLAINER-How worried should we be about blood clots linked to Astra, J&J vaccines? Reuters 1 hr ago
(Adds details following EMA warning label for J&J vaccine)
By John Miller and Ludwig Burger
ZURICH, April 21 (Reuters) - European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting.
J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. U.S. officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States.
By John Miller and Ludwig Burger ZURICH (Reuters) - European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting. J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. U.S. officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States. Britain s health regulator has recommended people under the age of 30 get an alternative COVID-19 vaccine, if possible, rather than the AstraZeneca shot, while some other European countries are only administering the shot to older people. Amid concerns that rare side effect reports could undermine confidence, vaccine and immunology experts said clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-1
April 21, 20216:18 PM UTC
Healthcare & PharmaceuticalsExplainer: How worried should we be about links of blood clots to AstraZenecaâs vaccine?
Ludwig BurgerJohn Miller
7 minutes read
Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez
European regulators said the benefits of using Johnson & Johnsonâs (JNJ.N)and AstraZenecaâs(AZN.L) COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting.
J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulatorâs guidance. U.S. officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States.